These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 16631684)

  • 21. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cadaveric renal transplantation in hepatitis B antigen-positive recipients using hepatitis B antigen-positive donor organs with lamivudine treatment.
    Kim JA; Huh W; Lee KW; Kim SJ; Kim YG; Kim DJ; Joh JW; Oh HY
    Transplant Proc; 2004 Jun; 36(5):1434-7. PubMed ID: 15251352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Settmacher U; Neuhaus R; Radke C; Berg T; Hopf U; Neuhaus P
    Liver Transpl; 2001 Nov; 7(11):976-82. PubMed ID: 11699034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safe use of livers from donors with positive hepatitis B core antibody.
    Manzarbeitia C; Reich DJ; Ortiz JA; Rothstein KD; Araya VR; Munoz SJ
    Liver Transpl; 2002 Jun; 8(6):556-61. PubMed ID: 12037788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach.
    Fábrega E; García-Suarez C; Guerra A; Orive A; Casafont F; Crespo J; Pons-Romero F
    Liver Transpl; 2003 Sep; 9(9):916-20. PubMed ID: 12942452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure.
    Abdelmalek MF; Pasha TM; Zein NN; Persing DH; Wiesner RH; Douglas DD
    Liver Transpl; 2003 Dec; 9(12):1253-7. PubMed ID: 14625824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.
    Lee WC; Wu MJ; Cheng CH; Chen CH; Shu KH; Lian JD
    Am J Kidney Dis; 2001 Nov; 38(5):1074-81. PubMed ID: 11684562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does hepatitis C virus affect the reactivation of hepatitis B virus following renal transplantation?
    Yen TH; Huang CC; Lin HH; Huang JY; Tian YC; Yang CW; Wu MS; Fang JT; Yu CC; Chiang YJ; Chu SH
    Nephrol Dial Transplant; 2006 Apr; 21(4):1046-52. PubMed ID: 16390851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen.
    Ahn HJ; Kim MS; Kim YS; Kim SI; Huh KH; Ju MK; Ahn SH; Han KH
    J Med Virol; 2007 Nov; 79(11):1655-63. PubMed ID: 17854044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic alteration of HBV markers on active HBV replicative recipients after liver transplantation: a preliminary report.
    Lu SC; Yan LN; Li B; Ma YK; Liu C; Wen TF; Lin QY; Zhao JC; Wang XB; Li XD; Qing S; Zhao LS; Liu C; Liu J; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):196-201. PubMed ID: 14599968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lamivudine for treating active hepatitis B in renal transplant recipients: a case report.
    Manani SM; Fabbian F; Catalano C; Bordin V; Vogel W; Di Landro D
    Clin Nephrol; 2000 Apr; 53(4):suppl 44-6. PubMed ID: 10809435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance.
    Ghisetti V; Marzano A; Zamboni F; Barbui A; Franchello A; Gaia S; Marchiaro G; Salizzoni M; Rizzetto M
    Liver Transpl; 2004 Mar; 10(3):356-62. PubMed ID: 15004761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients.
    Matsue K; Aoki T; Odawara J; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuch M
    Eur J Haematol; 2009 Oct; 83(4):357-64. PubMed ID: 19508685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation.
    Uhm JE; Kim K; Lim TK; Park BB; Park S; Hong YS; Lee SC; Hwang IG; Koh KC; Lee MH; Ahn JS; Kim WS; Jung CW; Kang WK
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):463-8. PubMed ID: 17382252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B; Samuel D
    Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis.
    Cheung CK; Lo CM; Man K; Lau GK
    Liver Transpl; 2010 Nov; 16(11):1314-23. PubMed ID: 21031547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.
    Hann HW; Fontana RJ; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Gardner SD; Brown N; Griffiths D;
    Liver Transpl; 2003 Jan; 9(1):49-56. PubMed ID: 12514773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
    Knöll A; Boehm S; Hahn J; Holler E; Jilg W
    J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
    Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.